Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

EMA Starts Review of Handling Errors with Depot Formulations of Leuprorelin Medicines

Handling errors during preparation and administration can cause that some patients receive insufficient amount of medicine
24 Mar 2020
Anticancer agents & Biologic therapy

The European Medicines Agency (EMA) announced that it has started a review of leuprorelin medicines after reports indicated that handling errors with the products during preparation and administration can cause some patients to receive insufficient amounts of their medicine, thus reducing the benefits of treatment.

This review covers depot formulations which are given by injection under the skin or into a muscle and release the active substance slowly over 1 to 6 months. These include implants as well as powders and solvents for the preparation of injections.

Several of these formulations require complex steps to prepare the injection. Handling errors with these formulations have reportedly led to problems such as leakages from the syringe or failure to deliver implants from the applicator.

EMA’s safety committee, Pharmacovigilance Risk Assessment Committee (PRAC), will now evaluate all available data and determine whether measures are needed to ensure that the medicines are prepared and administered appropriately.

While the review is ongoing, healthcare professionals should carefully follow the handling instructions for leuprorelin medicines. Patients prescribed leuprorelin medicines who have any concerns should discuss them with their doctor.

Depot formulations of leuprorelin medicines are used to treat prostate cancer, breast cancer, endometriosis, symptomatic uterus myomatosus, uterine fibrosis and early puberty. They include implants as well as powders and solvents for the preparation of injections.

Leuprorelin medicines are also available as daily injections but this formulation is not included in the review as there have been no reports of handling errors with this formulation.

Leuprorelin medicines have been authorised via national procedures. They are marketed in many EU countries and are available under several brand names, including Eligard, Eliprogel, Enantone, Ginecrin, Lupron, Lutrate, Politrate, and Procren.

The review of leuprorelin depot medicines has been initiated at the request of Germany, under Article 31 of Directive 2001/83/EC.

The PRAC will make a set of recommendations. As leuprorelin medicines are all authorised nationally, the PRAC recommendations will be forwarded to the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), which will adopt a position. The CMDh is a body representing EU Member States as well as Iceland, Leichtenstein and Norway. It is responsible for ensuring harmonised safety standards for medicines authorised via national procedures across the EU.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.